- Conditions
- Obstructive Sleep Apnea
- Interventions
- Acetazolamide, Atomoxetine and eszopiclone, Placebo, Trazodone
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1297–1320
of 4,189
matching trials from the local directory fallback.
- Conditions
- Cancer, Myeloid Neoplasm
- Interventions
- Behavioral Placebo Control, GO-EXCAP Mobile App
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Bronchopulmonary Dysplasia (BPD), Critical Illness, Premature Births
- Interventions
- Placebo, montelukast 4 mg granule
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 7 Days to 28 Days
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Amherst, Massachusetts • Las Vegas, Nevada + 2 more
- Conditions
- Triglycerides
- Interventions
- Astaxanthin, Curcumin (Longvida™), Half Dose Curcumin (Longvida™), Placebo Control
- Dietary Supplement · Other
- Lead sponsor
- Medinutra LLC
- Other
- Eligibility
- 21 Years to 59 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dublin, Ohio
- Conditions
- Depression
- Interventions
- Placebo, Visbiome
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 15 Years to 24 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Brain Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Genitourinary Cancer, Gynecologic Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Lymphoid Leukemia, Melanoma, Mycosis Fungoides, Myeloma Multiple, Non-hodgkin Lymphoma, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, Sarcoma, Urinary Bladder Cancer
- Interventions
- Placebo, Riluzole
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Hemiparesis, Stroke
- Interventions
- Active rTMS, Open Placebo, Sham rTMS
- Device · Dietary Supplement
- Lead sponsor
- Spaulding Rehabilitation Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Placebo Administration, Questionnaire Administration
- Procedure · Dietary Supplement · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia • Buffalo, New York
- Conditions
- HIV Infections
- Interventions
- Midazolam, Placebo, VH4770359
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Ketone Monoester, Placebo - Control
- Interventions
- Ketone Monoester (KE), Placebo
- Dietary Supplement
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Migraine
- Interventions
- Placebo, Psilocybin
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Alzheimer Disease
- Interventions
- Lemborexant 10 mg, Lemborexant 20mg, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Interventions
- Inhaled Treprostinil, Placebo, Treprostinil Ultrasonic Nebulizer
- Drug · Device
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- IC-MPGN
- Interventions
- Placebo, iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 18 more
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Abelacimab, Placebo
- Biological · Drug
- Lead sponsor
- Anthos Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 143 more
- Conditions
- C3G
- Interventions
- Placebo, iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more
- Conditions
- Alzheimer Disease, Sleep
- Interventions
- Placebo, Suvorexant 20 mg
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease, Memory Impairment, Mild Cognitive Impairment
- Interventions
- CORT108297, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Parkinson's Disease (PD)
- Interventions
- EC5026 oral tablet, Placebo
- Drug
- Lead sponsor
- EicOsis Human Health Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Erectile Dysfunction, Prostate Cancer
- Interventions
- Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in clinic, Placebo in the OR
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 40 Years to 70 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Degenerative Disc Disease, Neuropathic Pain, Spinal Cord Injuries, Spinal Stenosis, Spondylosis
- Interventions
- EC5026 oral tablet, Placebo oral tablet
- Drug
- Lead sponsor
- EicOsis Human Health Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Heart Failure
- Interventions
- Finerenone, Placebo
- Drug
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more
- Conditions
- Hyperglycemia, Prediabetic State
- Interventions
- Placebo, Zinc Gluconate 30 MG
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania